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Abstract
Binding of natural anti-pig antibodies in humans and nonhuman primates to carbohydrate antigens 
expressed on the transplanted pig organ, the most important of which is galactose-α1,3-galactose 
(Gal), activate the complement cascade, which results in destruction of the graft within minutes or 
hours, known as hyperacute rejection. Even if antibody is removed from the recipient’s blood by 
plasmapheresis, recovery of antibody is associated with acute humoral xenograft rejection. If 
immunosuppressive therapy is inadequate, the development of high levels of T cell-dependent 
elicited anti-pig IgG similarly results in graft destruction, though classical acute cellular rejection 
is rarely seen. Vascular endothelial activation by low levels of anti-nonGal antibody, coupled with 
dysregulation of the coagulation-anticoagulation systems between pigs and primates, leads to a 
thrombotic microangiopathy in the graft that may be associated with a consumptive coagulopathy 
in the recipient. The most successful approach to overcoming these barriers is by genetically-
engineering the pig to provide it with resistance to the human humoral and cellular immune 
responses and to correct the coagulation discrepancies between the two species. Organs and cells 
from pigs that (i) do not express the important Gal antigen, (ii) express a human complement-
regulatory protein, and (iii) express a human coagulation-regulatory protein, when combined with 
an effective immunosuppressive regimen, have been associated with prolonged pig graft survival 
in nonhuman primates.
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Organ xenotransplantation
When interest developed in using the pig as a potential organ source for humans, little was 
known about the immunology of pig-to-primate organ transplantation. Studies in the 
clinically-relevant (wild-type) pig-to-baboon model indicated that very rapid graft 
destruction occurred, usually within minutes [1–3].
Hyperacute rejection
When a pig organ is transplanted into a human or nonhuman primate, there is an immediate 
immune response, known as hyperacute rejection (Figure 1A). This has been defined as 
destruction of the graft within 24 hours, but it frequently occurs within the first hour, and is 
related to binding of primate natural (preformed) anti-pig antibodies to the graft vascular 
endothelial cells. Antibody deposition initiates complement-mediated injury of the 
endothelial lining, resulting in thrombosis, interstitial hemorrhage and edema that disrupts 
graft function [4,5].
It was subsequently determined that the most important antibodies (IgM and IgG) bind to a 
carbohydrate epitope, galactose-α1,3-galactose (Gal), expressed on the pig vascular 
endothelium (reviewed in [6]). This oligosaccharide is present in all other mammals, with 
the exception of humans and Old World nonhuman primates (e.g., great apes, baboons, Old 
World monkeys) (reviewed by [7]). These primate species lost expression of Gal several 
million years ago, probably from a genetic mutation, and the absence of Gal resulted in 
primates making antibodies against this now ‘foreign’ antigen.
These antibodies develop during neonatal life [8,9], and are almost certainly a response to 
Gal-expressing viruses and microorganisms that colonize the primate’s gastrointestinal tract 
[10]. These ‘natural’ or ‘preformed’ antibodies differ from ‘elicited’ antibodies that develop 
after direct exposure to an antigen, e.g., antibodies that develop after an organ transplant.
As the causative factors associated with hyperacute rejection of a xenograft were seen to be 
similar to those of ABO-incompatible allograft rejection [11], a similar approach was taken 
to prevent rejection by depleting the recipient of these anti-pig antibodies by plasmapheresis 
[3] or, later, by depleting specifically anti-Gal antibodies by immunoaffinity columns [12]. 
In addition, again based on experience with ABO-incompatibility studies, the intravenous 
infusion of natural or synthetic Gal oligosaccharides was tested, which were bound by anti-
Gal antibody and then excreted [13,14]. Even when combined with conventional 
immunosuppressive therapy, these approaches were only partially successful; they delayed 
antibody-mediated rejection, but the graft was lost when antibody levels recovered.
An alternative or additional approach was to administer an agent that depleted or inhibited 
complement, e.g., cobra venom factor, which extended graft survival significantly [15,16], 
but again had only a temporary effect.
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When genetic modification of the organ-source pig became possible, a different approach to 
overcoming hyperacute rejection was suggested by Dalmasso (in the USA) [17] and, 
independently, by White (in the UK) [18] and their respective colleagues. The cells of 
humans are to some extent protected from complement-mediated injury by the presence of 
complement-regulatory proteins on their surfaces, e.g., decay accelerating factor (DAF, 
CD55), or membrane cofactor protein (MCP, CD46). Although pig cells have equivalent 
complement-regulatory proteins, these are less able to provide protection from the effects of 
human complement. Dalmasso and White suggested introducing into the pig a transgene for 
a human complement-regulatory protein. In the mid-1990s, this was achieved by several 
groups, and represent the first genetically-engineered pigs directed towards 
xenotransplantation (reviewed by [19]).
When the importance of Gal had been established, it was suggested that the gene that 
produced the enzyme that attached Gal terminally on oligosaccharide chains, α1,3-
galactosyltransferase, should be deleted or knocked-out [20]. The first α1,3-
galactosyltransferase gene-knockout (GTKO) pig was not produced until 2003 [21,22]. 
Initial studies showed protection from hyperacute rejection [23,24].
Acute humoral xenograft rejection
Even when hyperacute rejection was prevented, a similar form of rejection occurred, 
generally within a few days or weeks - acute humoral xenograft rejection (AHXR). It is also 
related to the deposition of antibody and complement, which activate the endothelium [25], 
and the effect of graft infiltration by innate immune cells (e.g., polymorphonuclear 
leukocytes, macrophages, NK cells) that together destroy the graft. When a GTKO pig organ 
is transplanted, the antibodies involved are natural antibodies directed against nonGal 
antigens, the exact nature of which remains uncertain, although two have been identified 
(see below).
The combination of GTKO and a human complement-regulatory protein was even more 
successful in preventing early graft failure of a transplanted pig organ [26,27].
The adaptive immune response
If both hyperacute and AHXR are prevented, but immunosuppressive therapy is inadequate, 
a T-cell dependent elicited antibody response develops, resulting in high levels of anti-pig 
IgG [28]. Binding of these antibodies to the vascular endothelium initiates histopathological 
changes indistinguishable from AHXR. Surprisingly, acute cellular rejection, as seen in the 
majority of allotransplants, has virtually never been recorded after pig-to-nonhuman primate 
organ xenotransplantation. This is most likely because the humoral response is more rapid 
and overwhelms the cellular response, though T and B cells may well be seen in the graft.
Although high doses of conventional immunosuppressive therapy, e.g., tacrolimus, 
mycophenolate mofetil, and corticosteroids, have delayed graft failure [29,30], they have 
been associated with a relatively high incidence of infectious complications. A potentially 
more successful approach has been with the administration of agents that are directed to 
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costimulation blockade, first introduced into xenotransplantation by Buhler in 2000 ([28]; 
reviewed in [31]).
Here again, genetic engineering of the organ-source pigs may prove beneficial (reviewed in 
[31]) Pigs transgenic for the T cell costimulation blockade agent, CTLA4-Ig, have been 
produced successfully [32], but, because of the high levels of soluble CTLA4-Ig produced, 
proved to immunocompromised, prohibiting their long-term survival. Subsequent efforts 
have been directed towards expressing CTLA4-Ig in only selected tissues, e.g., the vascular 
endothelium or the islets.
A second approach has been to express a mutant human Major Histocompatibility Complex 
(MHC) class II transactivator transgene in the pig. This mutation results in downregulation 
of swine leukocyte class II expression, and inhibits upregulation of expression after 
activation of the pig endothelial cells, thus reducing the human T cell response [33]. 
Recently, MHC class I-knockout pigs have been produced [34], and their effect as donors of 
xenografts is being investigated.
Coagulation dysfunction
Even when hyperacute rejection, AHXR, and the T cell response were successfully 
controlled, it became increasingly clear that abnormal coagulation within the vessels of the 
graft played a significant role in graft failure (reviewed by [35,36]). Coagulation 
dysregulation can result in the development of a thrombotic microangiopathy, in which the 
vasculature of the organ is steadily occluded by thrombus, resulting in ischemic necrosis of 
the tissues (Figure 1B) [37,38].
Small vessels in the graft become occluded by fibrin and platelet aggregation. When 
advanced, the loss of platelets and clotting factors in the graft may result in a consumptive 
coagulopathy in the recipient primate [39]. The initiating cause of the thrombotic 
microangiopathy almost certainly results from activation of the vascular endothelial cells by 
antibody, complement, and/or innate immune cells, changing the phenotype of the cells from 
an anticoagulant state to a procoagulant state. However, there are several known 
incompatibilities in the coagulation/anticoagulation factors between pig and primate that 
almost certainly contribute to coagulation dysregulation between graft and host [35,36]. 
Consumptive coagulopathy appears to develop much more rapidly in nonhuman primates 
with pig kidney grafts whereas a thrombotic microangiopathy predominates after pig heart 
transplantation, followed terminally by a consumptive coagulopathy [23,39,40].
Efforts were made to control this problem by the administration of anticoagulants and/or 
anti-thrombotic agents to the recipient nonhuman primate, with partial success [37], but 
evidence was presented indicating that increased immunosuppression was more effective 
than anticoagulant agents [41]. This problem is also steadily being overcome by further 
genetic manipulation of the organ source pig, e.g., by the insertion of an ‘anticoagulant’ or 
‘anti-thrombotic’ gene, such as thrombomodulin, endothelial protein C receptor (EPCR), 
tissue factor pathway inhibitor (TFPI), or CD39 [35,36], resulting in extended graft survival 
[42].
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Ezzelarab has presented evidence that an inflammatory response precedes the development 
of coagulation dysfunction, emphasizing the inter-relationships between the immune, 
coagulation and inflammatory responses [43]. In particular, the potential role of 
interleukin-6 (IL-6) has been highlighted [43,44], (and the beneficial effect of an IL-6R 
antagonist is being explored [44].
Graft vasculopathy (chronic rejection)
Chronic rejection (graft vasculopathy) has been documented in some pig cardiac xenografts 
that have functioned for >3 months in baboons, and has a similar histopathological 
appearance to that seen after allotransplantation (Figure 1C) [45]. Some encouragement, 
however, is provided by the ongoing studies of Mohiuddin et al in which graft vasculopathy 
has not been reported in heart grafts from GTKO/hCD46 pigs expressing human 
thrombomodulin, with follow-up in one case for more than two years [42].
Remaining barriers
The immunobiological problems associated with transplantation of pig livers [46] and lungs 
[47] are more complex, and to date have limited graft survival to days rather than weeks, 
months or years (reviewed in [48]). Humans are known to have natural antibodies to at least 
two other antigens on pig cells, namely N-glycolylneuraminic acid (NeuGc) (reviewed in 
[49]) and β1,4 N-acetylgalactosaminyltransferase [50]. As most nonhuman mammals 
express NeuGc, including Old World nonhuman primates (even chimpanzees), it is difficult 
to investigate its effect in in vivo experimental models, e.g., pig-to-baboon organ 
transplantation. Most information to date, therefore, has been obtained from staining of pig 
tissues for expression of NeuGc, and laboratory assays. There is increasing evidence that 
this antibody-antigen interaction will need to be prevented if a pig organ or cells are 
transplanted into a human patient. The recent production of pigs in which the gene 
responsible for producing NeuGc has been deleted (as well as that for Gal) is a major step 
towards this goal [51].
Cell and tissue xenotransplantation
Pigs could also act as a source of other tissues, such as pancreatic islets (for the treatment of 
diabetes), neuronal cells (for conditions such as Parkinson’s disease), corneas (for patients 
with corneal blindness), and red blood cells (for clinical transfusion). The immunobiology of 
graft injury is similar to that seen in pig organs, but a T cell-induced response appears to 
play a more important role, as in allografts.
Considerable attention has been paid to the transplantation of porcine islets of Langerhans as 
a means of providing a source of insulin in patients with Type 1 diabetes (reviewed in [52]). 
Techniques are available, e.g., by the use of an insulin-specific promoter, that enable a 
desired transgene to be expressed in the islets alone, thus negating any potential detrimental 
effects (e.g., systemic anticoagulation) that might result from widespread expression in the 
pig [53]. However, success has not yet been consistent, and further study is required.
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The cellular immune response can be inhibited by currently-available immunosuppressive 
agents, particularly by those that result in blockade of T cell costimulation. Both wild-type 
and genetically-engineered adult porcine islets have been demonstrated to maintain 
normoglycemia in diabetic monkeys for periods in excess of 1 year [53–55]. Wild-type 
neonatal pig islets have also maintained normoglycemia in diabetic monkeys for >6 months 
[56,57].
Induction of tolerance to pig organs and cells
The ideal goal in both allotransplantation and xenotransplantation is the induction of 
immunological ‘tolerance’, in which the immune system of the recipient is manipulated so 
that the transplanted organ or cells are accepted as ‘self’ with no effort made to reject them. 
The identification and availability of the ‘donor’ prior to the transplant allows the procedure 
to be ‘timed’, and may facilitate the induction of tolerance to the transplanted organs of 
cells. Efforts in this respect have been made through inducing hematopoietic cell chimerism 
[58,59] or by pig thymic transplantation [24], but without complete success to date.
Conclusion
With the increasing variety of genetically-engineered pigs (Table 1) and immunosuppressive 
and anti-inflammatory agents now becoming available, it is likely the remaining 
immunobiological problems will be resolved.
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– Several barriers need overcoming if pig organs are to be transplanted 
successfully
– Both the innate and adaptive immune responses need to be overcome
– Additional barriers include coagulation dysfunction and an inflammatory 
response Most barriers can be overcome by the genetic engineering of the 
pigs
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Summary of the known major immunologic barriers to pig-to-primate heart transplantation. 
(Reproduced with permission from Zhu X, et al, J Heart Lung Transplant 2007;26:210–
218.)
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Table 1
Genetically-engineered pigs produced for xenotransplantation research
Complement regulation by human complement-regulatory gene expression:
CD46 (membrane cofactor protein)
CD55 (decay-accelerating factor)
CD59 (protectin or membrane inhibitor of reactive lysis)
Gal or nonGal antigen ‘masking’ or deletion:
human H-transferase gene expression (expression of blood type O antigen)
endo-beta-galactosidase C (reduction of Gal antigen expression)
α1,3-galactosyltransferase gene-knockout (GTKO)
Cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene-knockout (NeuGc-KO)
β4GalNT2 (β1,4 N-acetylgalactosaminyltransferase) gene-knockout (β4GalNT2-KO)
Suppression of cellular immune response by gene expression or downregulation
CIITA-DN (MHC class II transactivator knockdown, resulting in swine leukocyte antigen class II knockdown)
Class I MHC-knockout (MHC-I-KO)
HLA-E/human β2-microglobulin (inhibits human natural killer cell cytotoxicity)
human FAS ligand (CD95L)
human GnT-III (N-acetylglucosaminyltransferase III) gene
porcine CTLA4-Ig (Cytotoxic T-Lymphocyte Antigen 4 or CD152)
human TRAIL (tumor necrosis factor-alpha-related apoptosis-inducing ligand)
Anticoagulation and anti-inflammatory gene expression or deletion
von Willebrand factor (vWF)-deficient (natural mutant)
human tissue factor pathway inhibitor (TFPI)
human thrombomodulin
human endothelial protein C receptor (EPCR)
human CD39 (ectonucleoside triphosphate diphosphohydrolase-1)
Anticoagulation, anti-inflammatory, and anti-apoptotic gene expression
human A20 (tumor necrosis factor-alpha-induced protein 3)
human heme oxygenase-1 (HO-1)
Porcine asialoglycoprotein receptor 1 gene-knockout (ASGR1-KO) (decreases platelet phagocytosis)
Human signal regulatory protein α (SIRPα) (decreases platelet phagocytosis by ‘self’ recognition)
Prevention of porcine endogenous retrovirus (PERV) activation
PERV siRNA
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